Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03001362
NA

Patients With Rectal Cancer: a "Wait-and-see" Approach

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

View on ClinicalTrials.gov

Summary

Patients with histologically proven adenocarcinoma of the rectum will receive pelvic radiotherapy to a dose of 45Gy in 25 fractions with a tumor boost to a dose of 9Gy in 5 fractions (thus total of 54Gy/30Fx to the primary tumor), combined with radio sensitizing chemotherapy. Patients will then be closely monitored, through endoscopy and imaging, for response to treatment and relapse. Salvage oncologic surgery to be offered if there is failure to achieve complete clinical response or in the event of a loco regional relapse.

Official title: Radical External Beam Chemoradiation in Patients With Rectal Cancer: a "Wait-and-see" Approach

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2015-03

Completion Date

2026-01

Last Updated

2025-05-15

Healthy Volunteers

No

Interventions

RADIATION

Radical external beam radiotherapy

pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.

Locations (2)

McGill University Health Center-Cedars Cancer Centre

Montreal, Quebec, Canada

McGill University Health Centre- Cedars Cancer Centre

Montreal, Quebec, Canada